Cargando…

Statin-Induced Autoimmune Necrotizing Myositis: A Case Report

Statin therapy is considered one of the main therapies indicated to reduce the risk of cardiovascular death in patients with atherosclerotic cardiovascular disease. Maximal risk reduction is linked to the degree of reduction of the low-density lipoprotein cholesterol; therefore, high-intensity dosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Almadhoun, Hussein, Mesiha, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588154/
https://www.ncbi.nlm.nih.gov/pubmed/36299921
http://dx.doi.org/10.7759/cureus.29475
_version_ 1784814065935187968
author Almadhoun, Hussein
Mesiha, Nancy
author_facet Almadhoun, Hussein
Mesiha, Nancy
author_sort Almadhoun, Hussein
collection PubMed
description Statin therapy is considered one of the main therapies indicated to reduce the risk of cardiovascular death in patients with atherosclerotic cardiovascular disease. Maximal risk reduction is linked to the degree of reduction of the low-density lipoprotein cholesterol; therefore, high-intensity dosing is required with coronary artery disease. Musculoskeletal side effects are reported with the use of statin, especially at high doses. Although myopathy is a common side effect, autoimmune-mediated necrotizing myositis is a rare side effect usually related to the development of hydroxymethylglutaryl-coenzyme A reductase antibodies which attack the muscles leading to swelling manifesting as muscle weakness and pain, as presented in our case report.
format Online
Article
Text
id pubmed-9588154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-95881542022-10-25 Statin-Induced Autoimmune Necrotizing Myositis: A Case Report Almadhoun, Hussein Mesiha, Nancy Cureus Cardiology Statin therapy is considered one of the main therapies indicated to reduce the risk of cardiovascular death in patients with atherosclerotic cardiovascular disease. Maximal risk reduction is linked to the degree of reduction of the low-density lipoprotein cholesterol; therefore, high-intensity dosing is required with coronary artery disease. Musculoskeletal side effects are reported with the use of statin, especially at high doses. Although myopathy is a common side effect, autoimmune-mediated necrotizing myositis is a rare side effect usually related to the development of hydroxymethylglutaryl-coenzyme A reductase antibodies which attack the muscles leading to swelling manifesting as muscle weakness and pain, as presented in our case report. Cureus 2022-09-22 /pmc/articles/PMC9588154/ /pubmed/36299921 http://dx.doi.org/10.7759/cureus.29475 Text en Copyright © 2022, Almadhoun et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Almadhoun, Hussein
Mesiha, Nancy
Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
title Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
title_full Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
title_fullStr Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
title_full_unstemmed Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
title_short Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
title_sort statin-induced autoimmune necrotizing myositis: a case report
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588154/
https://www.ncbi.nlm.nih.gov/pubmed/36299921
http://dx.doi.org/10.7759/cureus.29475
work_keys_str_mv AT almadhounhussein statininducedautoimmunenecrotizingmyositisacasereport
AT mesihanancy statininducedautoimmunenecrotizingmyositisacasereport